Zymeworks (ZYME) Other Non-Current Assets (2021 - 2026)
Zymeworks recorded quarterly Other Non-Current Assets of $6.7 million in Q1 2026, little changed quarter-over-quarter from $6.7 million in Q4 2025, and down 26.87% year-over-year from $9.1 million in Q1 2025.
Zymeworks' Other Non-Current Assets history runs 6 years deep, the most recent figure standing at $6.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 26.87% year-over-year to $6.7 million; the TTM figure through Mar 2026 stood at $6.7 million (down 26.87% YoY), while the FY2025 annual figure was $6.7 million, down 25.17% from the prior year.
- Other Non-Current Assets came in at $6.7 million for Q1 2026 at Zymeworks, roughly flat from $6.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $16.9 million in Q1 2023 to a low of $6.7 million in Q1 2026.
- A 5-year average of $9.5 million and a median of $7.9 million in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets grew 25.93% in 2022 and slumped 54.54% in 2024, its largest moves.
- Zymeworks' Other Non-Current Assets stood at $15.7 million in 2022, then sank by 51.9% to $7.6 million in 2023, then gained by 17.88% to $8.9 million in 2024, then retreated by 25.17% to $6.7 million in 2025, then declined by 0.33% to $6.7 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $6.7 million, $6.7 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 6.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 6.67 Mn |
| Sep 30, 2025 | 7.39 Mn |
| Jun 30, 2025 | 8.86 Mn |
| Mar 31, 2025 | 9.10 Mn |
| Dec 31, 2024 | 8.92 Mn |
| Sep 30, 2024 | 7.23 Mn |
| Jun 30, 2024 | 7.18 Mn |
| Mar 31, 2024 | 7.68 Mn |
| Dec 31, 2023 | 7.57 Mn |
| Sep 30, 2023 | 8.29 Mn |
| Jun 30, 2023 | 7.91 Mn |
| Mar 31, 2023 | 16.89 Mn |
| Dec 31, 2022 | 15.73 Mn |
| Sep 30, 2022 | 16.45 Mn |
| Dec 31, 2021 | 12.49 Mn |